Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

doi:10.1186/s12916-022-02361-w

	Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
	Song, Zhengbo 6; Lou, Guangyuan 7; Wang, Yina 4; Yang, Zhiping 1; Wang, Wenxian 7; Ji, Yongling 5; Chen, Shiqing 3; Xu, Chunwei 2; Hu, Xiao 5; Zhang, Yiping 7
刊名	BMC MEDICINE
	2022-05-10
卷号	20
关键词	Thymic epithelial tumors Apatinib Efficacy Toxicities
ISSN号	1741-7015
DOI	10.1186/s12916-022-02361-w
通讯作者	Zhang, Yiping(yi_ping_zhang@163.com)
英文摘要	Background Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs. Methods This was an open-label, single-arm, phase II trial at three centers in China. Patients with TET who had progressed after failure of at least one line of platinum-based chemotherapy were enrolled. Patients received apatinib 500 mg orally per day. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Results From June 29, 2017, to April 18, 2019, 25 patients were enrolled. At data cut off (September 30, 2021), one patient achieved complete response, nine achieved partial response, and 11 achieved stable disease, with an ORR of 40% (95% CI 21-61%) and DCR of 84% (95% CI 64-95%). The median PFS was 9.0 (95% CI 5.4-12.6) months. The median OS was 24.0 (95% CI 8.2-39.8) months. All patients reported treatment-related adverse events (TRAEs). Grade 3 TRAEs occurred 26 times in 15 patients. No grade 4 or 5 toxicities occurred. Conclusions This is the first trial of apatinib for the treatment of TETs. Apatinib showed promising antitumor activity and the toxicities were tolerable and manageable.
WOS关键词	ENDOTHELIAL-GROWTH-FACTOR ; DOUBLE-BLIND ; CARCINOMA ; CHEMOTHERAPY ; THYMOMA ; PEMBROLIZUMAB ; SORAFENIB ; RECEPTORS ; EFFICACY ; OUTCOMES
WOS研究方向	General & Internal Medicine
语种	英语
出版者	BMC
WOS记录号	WOS:000792624100001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130819]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Yiping
作者单位	1.First Hosp Jiaxing, Dept Med Oncol, Jiaxing 314000, Zhejiang, Peoples R China 2.Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China 3.3D Med Inc, Med Dept, Shanghai 201114, Peoples R China 4.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Med Oncol, Hangzhou 310000, Zhejiang, Peoples R China 5.Univ Chinese Acad Sci, Dept Radiotherapy Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 6.Univ Chinese Acad Sci, Dept Clin Trial, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 7.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Song, Zhengbo,Lou, Guangyuan,Wang, Yina,et al. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial[J]. BMC MEDICINE,2022,20.
APA	Song, Zhengbo.,Lou, Guangyuan.,Wang, Yina.,Yang, Zhiping.,Wang, Wenxian.,...&Zhang, Yiping.(2022).Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.BMC MEDICINE,20.
MLA	Song, Zhengbo,et al."Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial".BMC MEDICINE 20(2022).